DURAVYU’s Phase 3 LUGANO Results Reveal Compelling Efficacy and Reduced Treatment Burden in Wet AMD
Market Chameleon (Tue, 18-Aug 9:55 AM)
DURAVYU Reduces Wet AMD Treatment Burden by 42%: Phase 3 LUGANO Results Highlight Supplement-Free Durability
Market Chameleon (Mon, 17-Aug 7:06 AM)
EyePoint Wraps Up Phase 3 DURAVYU Enrollment Early, Signaling Strong Momentum for Diabetic Macular Edema Progress
Market Chameleon (Thu, 30-Jul 9:41 AM)
